Answers are grounded in this paper and cite their sources.
In medical school, students learn that the diagnostic criteria for preeclampsia are new-onset hypertension and proteinuria after 20 weeks of gestation. An accurate diagnosis is essential, because preeclampsia is a leading cause of iatrogenic prematurity; the sole known “cure” for preeclampsia is delivery of the placenta. However, in clinical practice, the diagnosis of preeclampsia may be more nuanced than the classic textbook presentation. In a subset of patients, severe preeclampsia and even eclampsia (i.e., the presence of seizures) may present atypically in the absence of either hypertension or proteinuria. Diagnosing preeclampsia is further complicated by the fact that signs and symptoms of preeclampsia overlap with those of other medical conditions seen in pregnancy, such as liver disease, renal disease, chronic hypertension, and idiopathic thrombocytopenic purpura. Moreover, the standard clinical diagnostic criteria, such as hypertension or proteinuria, are not sufficiently accurate to predict adverse outcomes associated with the disease. The American College of Obstetricians and Gynecologists recently released new guidelines modifying the diagnostic criteria for preeclampsia that broaden the inclusion criteria to further reflect the heterogeneity of the clinical presentation (1). Current emphasis on overdiagnosis may improve maternal outcomes but may also lead to worse neonatal outcomes, because iatrogenic preterm delivery could result from significant misclassification of the disease. Preeclampsia is a leading cause of maternal mortality in developed and developing countries, making an improved diagnostic tool that is linked to the pathogenesis of the disease an important goal and a crucial step toward developing new treatments. Basic research has implicated a major pathogenic role for angiogenic imbalance in the placenta in the onset and progression of preeclampsia. High circulating concentrations of antiangiogenic factors such as soluble fms-like tyrosine kinase 1 (sFlt1)3 and low concentrations of proangiogenic factors such as placental growth factor (PlGF) released by the placenta contribute to systemic endothelial dysfunction and the development of the maternal hypertensive syndrome (2). This ratio of sFlt1:PlGF is increased in women with the disease and at least 4–5 weeks before the clinical signs and symptoms of preeclampsia manifest. Prior studies have confirmed the utility of the sFlt1:PlGF ratio in distinguishing thrombocytopenia caused by other idiopathic thrombocytopenic purpura from thrombocytopenia secondary to severe forms of preeclampsia such as HELLP syndrome (Hemolysis, Elevated Liver tests, Low Platelet count syndrome). Other studies have demonstrated that measurements of sFlt1 and PlGF can be used to differentiate preeclampsia from chronic hypertension and chronic kidney disease (2). However, assays used to measure these factors relied on manual immunoassays with large CVs, and therefore clinical utility was limited. Therefore, clinicians are left with a conglomeration of nonspecific tools to diagnose atypical presentations of preeclampsia, often relying on hospitalization, serial blood pressure measurements, laboratory surveillance, and assessment of fetal and maternal well-being for obstetrical management decisions. More recently, automated assays for both sFlt1 and PlGF have become available on multiple clinical laboratory platforms that have robust precision with CVs <5% (2). Using automated assays on clinical laboratory platforms, several observational studies have demonstrated the clinical utility of the serum sFlt1:PlGF ratio in the diagnosis of preeclampsia, with ROC curves >0.90 among patients with preterm preeclampsia. Moreover, measurements of sFlt1 and PlGF biomarkers in the third trimester outperform standard clinical laboratory parameters in identifying adverse maternal and fetal outcomes related to preeclampsia (3). This latter observation is not surprising, given that the antiangiogenic pathway is intimately involved in the disease pathogenesis and upstream of the resulting endothelial damage, such as an increased creatinine or transaminitis. Clinicians and researchers have postulated that sFlt1:PlGF may be used as a diagnostic tool with a high negative predictive value that would distinguish between diagnoses that have overlapping signs and symptoms with preeclampsia. However, prospective clinical trials have been limited. In a recent issue of the New England Journal of Medicine, Zeisler et al. performed a prospective, multicenter, observational study investigating the predictive value of the sFlt1:PlGF ratio measured on the Elecys platform in women with suspected preeclampsia (4). The authors performed an elegantly designed study, first identifying a ratio cutoff for a clinically significant predictive value in 500 women. In a subsequent validation study among 550 additional participants, the negative predictive value of the sFlt1:PlGF ratio was robust at 99.3% (greatly reducing the likelihood of a true diagnosis of preeclampsia in the next 7 days). Pregnant women with singleton gestations who were undergoing workup for a clinical suspicion of preeclampsia were included between 24 weeks 0 days to 36 weeks 6 days. Their sFlt1:PlGF ratio was correlated with the clinical diagnosis in 1-week and 4-week intervals. The signs and symptoms that prompted enrollment in the study correlated well with a preeclampsia evaluation in a clinical setting. In this study, preeclampsia was suspected but ultimately ruled out in 81% of patients with the use of the sFlt1:PlGF ratio. Due to the potential for morbidity and the heterogeneity of the disease, a preeclampsia evaluation typically requires serial laboratory studies, blood pressure surveillance, and a urinalysis for proteinuria. This evaluation is frequently performed as an inpatient. As described by Zeisler et al., an angiogenic sFlt1:PlGF ratio below 38, with its high negative predictive value, had the potential to reduce the need for hospitalizations and the likelihood of misclassification based on our current imprecise diagnostic tools. Additionally, the study demonstrated that this angiogenic ratio could accurately predict (negative predictive value 99.3%) the absence of an adverse fetal outcome (stillbirth, fetal growth restriction, preterm delivery, abruption, respiratory distress syndrome, necrotizing enterocolitis, and intraventricular hemorrhage) in the subsequent week of gestation. Therefore, the sFlt1:PlGF ratio, when used correctly, would help exclude a diagnosis of preeclampsia for 1 week of gestation, which has the potential to alter the standard of care for evaluating preeclampsia, particularly at a preterm gestational age. The clinical utility of this new diagnostic tool is an important question that warrants further study. The study did not evaluate any potential influence on hospitalization rate, preterm delivery rate, or fetal/maternal morbidity compared to the current standard care of evaluation and workup for preeclampsia. This trial limited participants to those in their second and third trimesters; the utility of these markers in the first trimester remains unknown. A first trimester biomarker that may be used to institute prophylaxis to prevent the angiogenic dysregulation of preeclampsia is needed. The use of this angiogenic ratio may therefore be best suited for use late in pregnancy for excluding conditions that may mimic preeclampsia or for guiding management of conditions such as preexisting chronic hypertension or renal disease, which are frequently challenging to discern from preeclampsia. Despite its excellent negative predictive value in the Zeisler et al. study, a high sFlt1:PlGF ratio had a positive predictive value of only 37% (not all patients with a positive test developed preeclampsia). This is not surprising, because many patients with even subclinical preeclampsia are delivered at 37 weeks. We do not know if these patients with high sFlt1/PlGF ratios would have developed clinical disease had the obstetrician not intervened. Consistent with this hypothesis, in a recent prospective study of 100 hospitalized patients admitted for suspected preeclampsia, Baltajian et al. demonstrated that the positive predictive value for sFlt1:PlGF ratio for indicated delivery within 2 weeks of presentation was 91% (5). Baltajian et al. also provided evidence that patients with no adverse maternal or neonatal outcomes had persistent low sFlt1:PlGF over days and weeks and argued that these assays may be used in the expectant management of patients with preterm preeclampsia. Further clinical investigation focusing on a high sFlt1:PlGF ratio and correlation for appropriate delivery timing to prevent severe maternal-fetal morbidity is prudent before using this ratio for universal screening for preeclampsia. When used correctly in women with an increased a priori likelihood of developing the disease, a diagnostic test such as the angiogenic ratio described by Zeisler et al. may revolutionize the diagnosis and management of preeclampsia in a select group of women suspected to have preeclampsia. In summary, a new era of molecular diagnostics for what was once considered a condition of unknown pathogenesis has set the stage for innovative clinical trials that may improve risk stratification and reduce neonatal morbidity from iatrogenic preterm delivery. Plasma angiogenic biomarkers may also be useful for identifying patients who are at risk for adverse outcomes and target specific therapies. Prospective clinical trials are needed to demonstrate that maternal and neonatal outcomes are improved when physicians are aware of the sFlt1:PlGF diagnostic test. soluble fms-like tyrosine kinase 1 placental growth factor.
No takes yet. Share an insight, caveat, or question.
Young et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: